Gemtuzumab and infection Patient Reports February 13, 2012

Gemtuzumab Side Effects Report #5000025-1
Gemtuzumab side effect was reported by a Consumer or non-health professional from NETHERLANDS on Apr 28, 2006. Female patient, 58 years of age, was diagnosed with myelodysplastic syndrome and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: infection , multi-organ failure, respiratory failure. Gemtuzumab dosage: 5 MG/M2 FOR ONE DAY ON DAY 7. During the same period patient was treated with CYTARABINE, IDARUBICIN. Patient died.

Gemtuzumab Side Effects Report #5035413-0
Gemtuzumab side effect was reported by a Consumer or non-health professional from NETHERLANDS on June 12, 2006. Female patient, 58 years of age, was diagnosed with myelodysplastic syndrome and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: bacteria urine identified, encephalopathy, hepatomegaly, infection , kidney enlargement, liver function test abnormal, lung infection, metastases to central nervous system, multi-organ failure. Gemtuzumab dosage: 5 MG/M2 FOR ONE DAY ON DAY 7. During the same period patient was treated with CYTARABINE, IDARUBICIN, COLISTIN, COMOX. Patient died.

Gemtuzumab Side Effects Report #5270233-3
Gemtuzumab side effect was reported by a Physician from NETHERLANDS on Mar 15, 2007. Female patient, weighting 149.9 lb, was diagnosed with myelodysplastic syndrome and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: infection , multi-organ failure, respiratory failure. Gemtuzumab dosage: 5MG/M2 FOR ONE DAY ON DAY 7. During the same period patient was treated with COMOX, COLISTIN, IDARUBICIN, CYTARABINE. Patient died on 01/02/2006.

Gemtuzumab Side Effects Report #4589490-1
Gemtuzumab side effect was reported by a Consumer or non-health professional from on Feb 10, 2005. Male patient, 37 years of age, was diagnosed with chronic myelomonocytic leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: capillary leak syndrome, condition aggravated, dyspnoea, fluid retention, hypoalbuminaemia, infection , lung infiltration, pleural effusion. Gemtuzumab dosage: 12.4 MG 1X PER 1 DAY. During the same period patient was treated with IDARUBICIN, CYTARABINE, ALLOPURINOL, ATENOLOL. Patient died.


Gemtuzumab Side Effects Report #4613932-6
Gemtuzumab side effect was reported by a Physician from on Mar 11, 2005. Male patient, 37 years of age, was diagnosed with chronic myelomonocytic leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: capillary leak syndrome, condition aggravated, hypoalbuminaemia, infection , lung infiltration. Gemtuzumab dosage: 12.4 MG 1X PER 1 DAY;. During the same period patient was treated with IDABRUBICIN, ALLOPURINOL, ATNOLOL. Patient died.

Gemtuzumab Side Effects Report #4628508-4
Gemtuzumab side effect was reported by a Consumer or non-health professional from on Apr 01, 2005. Male patient, 37 years of age, was diagnosed with chronic myelomonocytic leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: capillary leak syndrome, condition aggravated, dyspnoea, fluid retention, hypoalbuminaemia, infection , lung infiltration, pleural effusion. Gemtuzumab dosage: 12.4 MG 1X PER 1 DAY. During the same period patient was treated with CYTARABINE, IDARUBICIN, ALLOPURINOL, ATENOLOL. Patient died.

Gemtuzumab Side Effects Report #4927935-5
Gemtuzumab side effect was reported by a Consumer or non-health professional from DENMARK on Feb 10, 2006. Male patient was diagnosed with acute myeloid leukaemia recurrent and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blood creatine phosphokinase increased, blood lactate dehydrogenase increased, haemoglobin decreased, haemolysis, infection , neutrophil count increased, thrombocytopenia. Gemtuzumab dosage: 3.8 MG 1X PER 1 DASY, INTRAVENOUS. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN. Patient recovered.

Gemtuzumab Side Effects Report #5210315-5
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Jan 05, 2007. Male patient, 83 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blood lactate dehydrogenase increased, colitis ischaemic, disease progression, infection , intestinal haemorrhage, respiratory distress. Gemtuzumab dosage: 5 MG; SEE IMAGE. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, GLAZIDIM, TRIDECANAMINE, LEVOFLOXACIN, VORICONAZOLE, MEROPENEM, CYTARABINE. Patient died.

Gemtuzumab Side Effects Report #4867042-3
Gemtuzumab side effect was reported by a Health Professional from NETHERLANDS on Mar 10, 2002. Male patient, 53 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: asthenia, blast cells present, blood lactate dehydrogenase increased, hypertension, hypotension, infection , pancytopenia, pneumonia , respiratory failure. Gemtuzumab dosage: CYCLE 1 (13-OCT-98) : CYCLE 2 CYCLE INTRAVENOUS; 2 (02-NOV-98) : 9 MG/M (2). During the same period patient was treated with CIPROXIN, DIFLUCAN, TAVEGIL. Patient was hospitalized. Patient died.


Gemtuzumab Side Effects Report #5288624-3
Gemtuzumab side effect was reported by a Physician from ITALY on Mar 30, 2007. Male patient, weighting 136.7 lb, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: colitis ischaemic, disease progression, infection , respiratory distress. Gemtuzumab dosage: unknown. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, MEROPENEM, LEVOFLOXACIN, VORICONAZOLE, GLAZIDIM, TRIDECANAMINE. Patient died on 12/05/2006.

Gemtuzumab Side Effects Report #5889712-0
Gemtuzumab side effect was reported by a Physician from DENMARK on Sept 08, 2008. Female patient was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blood test abnormal, confusional state, convulsion, hypertension, infection , intravascular haemolysis. Gemtuzumab dosage: 5MG/M^2, TWO DOSES WITH A 3-WEEK INTERVAL. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN. Patient recovered.

Gemtuzumab Side Effects Report #4816477-3
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Oct 18, 2005. Female patient was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: infection . Gemtuzumab dosage: A SINGLE 9 MG/M^2 DOSE, INTRAVENOUS. Patient died.

Gemtuzumab Side Effects Report #4816480-3
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Oct 18, 2005. Female patient was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: infection . Gemtuzumab dosage: A SINGLE 9 MG/M^2 DOSE, INTRAVENOUS. Patient died.

Gemtuzumab Side Effects Report #4816481-5
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Oct 18, 2005. Female patient was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: infection . Gemtuzumab dosage: A SINGLE 9 MG/M^2 DOSE, INTRAVENOUS. Patient died.


Gemtuzumab Side Effects Report #4866861-7
Gemtuzumab side effect was reported by a Health Professional from GERMANY on Dec 14, 2005. Male patient, 70 years of age, was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: infection , myocardial infarction, ventricular tachycardia. Gemtuzumab dosage: 12.18 MG. During the same period patient was treated with RAMIPRIL. Patient was hospitalized. Patient died.